Kairos Pharma Ltd (KAPA) FinancialsKAPAKairos Pharma Ltd

Evaluating the bottom line, Kairos Pharma Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -113.96%, provide a clear picture of how effectively KAPA converts its operational activities into shareholder value.

In the context of the broader market, KAPA competes directly with industry leaders such as XRTX and GNPX. With a market capitalization of $1.80M, it holds a leading position in the sector. When comparing efficiency, KAPA's gross margin of N/A stands against XRTX's N/A and GNPX's N/A. Such benchmarking helps identify whether Kairos Pharma Ltd is trading at a premium or discount relative to its financial performance.

Kairos Pharma has shown a consistent pattern of financial losses, with net income to common shareholders being negative across the last several quarters. For example, in Q1 2026, the net income was -$1,654,000, and the EPS for the same quarter was -0.55. The company's gross profit has also been minimal, with only $120,000 reported in Q4 2025, indicating serious revenue challenges.